Tolvaptan Tablet
NDC Package 67877-635-33
Package Information
Tolvaptan tablets is a medication used by people who have a certain inherited kidney problem (autosomal dominant polycystic kidney disease-ADPKD). This formulation utilizes a tablet delivery system. Marketed by Ascend Laboratories, Llc, this product is identified by NDC 67877-635 and is authorized under FDA application ANDA211891.
Identification & Billing
- RxCUI: 2044363 - tolvaptan 60 MG Oral Tablet
- RxCUI: 849827 - tolvaptan 15 MG Hyponatremia Oral Tablet
- RxCUI: 849827 - Hyponatremia tolvaptan 15 MG Oral Tablet
- RxCUI: 849833 - tolvaptan 30 MG Hyponatremia Oral Tablet
- RxCUI: 849833 - Hyponatremia tolvaptan 30 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 67877 - Ascend Laboratories, Llc
- 67877-635 - Tolvaptan
- 67877-635-33 - 1 BLISTER PACK in 1 CARTON / 10 TABLET in 1 BLISTER PACK
- 67877-635 - Tolvaptan
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (67877-635). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 67877-635-33 identifies a specific commercial package of 1 blister pack in 1 carton / 10 tablet in 1 blister pack of Tolvaptan, a human prescription drug labeled by Ascend Laboratories, Llc. This tablet is formulated for oral use and contains tolvaptan as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Ascend Laboratories, Llc on September 07, 2022. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used by people who have a certain inherited kidney problem (autosomal dominant polycystic kidney disease-ADPKD). This inherited kidney problem leads to the growth of fluid-filled sacs (cysts) in your kidneys. Over time, the cysts grow in size, which can damage the way your kidneys work and lead to kidney failure. Tolvaptan belongs to a class of drugs known as vasopressin receptor antagonists. It works by slowing the growth of kidney cysts caused by ADPKD. This effect helps protect your kidneys from damage and failure. Different brands of this medication have different uses. Do not change brands of this medication unless directed by your doctor.
How is this Ascend Laboratories, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 67877063533. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.